Rank: 75
2016 Rank89
R&D Spend:$156,100,000
Fiscal year ending:12-31-16
Click here to see all 100

Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class—while empowering our community to take control of diabetes.

Dexcom G5® Mobile Continuous Glucose Monitoring System Now Available on the Apple Watch. Dexcom G5® Mobile Continuous Glucose Monitoring System Receives CE Mark. FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System. FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share.

Big 100 Mini Logo Key Personnel: Terrance Gregg, chairman; Kevin Sayer, CEO & president; Andrew Balo, EVP, clinical, regulatory & global access; Rick Doubleday, EVP & CCO; Jacob Leach, SVP, R&D; John Lister, GM, Europe, Middle East & Africa; Jeffrey Moy, SVP, operations; Steven Pacelli, SVP, strategy & corporate development; Annika Jimenez, SVP, data; Claudia Graham, SVP, global access; Don Abbey, EVP, quality & IT; Heather Ace, SVP, HR; Kevin Sun, VP & interim CFO.;

6340 Sequence Drive
San Diego, CA